ERBB2 and intrahepatic cholangiocarcinoma: Roughly 13% of gallbladder cancers, 18% of extrahepatic cholangiocarcinoma, and 5% of intrahepatic cholangiocarcinoma overexpress HER-2 via ERBB2 or ERBB3 mutations [33,34,35].